Five-year Efficacy and Safety of Tafasitamab in Patients With Relapsed or Refractory DLBCL: Final Results From the Phase II L-MIND Study

May 25, 2023

Grzegorz S. Nowakowski, MD, Mayo Clinic

In Partnership With:

Expert hematologist-oncologist Grzegorz Nowakowski, MD, reviews data from the 5-year analysis of the L-MIND study combining tafasitamab with lenalidomide in relapsed/refractory diffuse large B-cell lymphoma.

Related Videos

Experts on prostate cancer

Experts on prostate cancer

Tycel Phillips, MD

Expert on lung cancer

Expert on ALL

Morie A. Gertz, MD

Lida A. Mina, MD

Experts on prostate cancer

Experts on prostate cancer

Thomas M. Habermann, MD

Related Content

ASCO 2023 Insights: ADCS, Next-Generation TKIs, and More Lead Data Pack Ahead of Annual Meeting

Andreeff Sheds Light on the Evaluation of the E-selectin Antagonist Uproleselan in AML

Voruciclib With or Without Venetoclax Shows Safety, Activity in R/R AML, B-cell Malignancies

FDA Approval Insights: Omidubicel in Blood Cancers Requiring Transplant

Omidubicel Approval Represents Key Advance for Patients With Blood Cancers Requiring Transplant

Birtamimab Under Investigation in Mayo Stage IV AL Amyloidosis

ASCO 2023 Insights: ADCS, Next-Generation TKIs, and More Lead Data Pack Ahead of Annual Meeting

Andreeff Sheds Light on the Evaluation of the E-selectin Antagonist Uproleselan in AML

Voruciclib With or Without Venetoclax Shows Safety, Activity in R/R AML, B-cell Malignancies

FDA Approval Insights: Omidubicel in Blood Cancers Requiring Transplant

Omidubicel Approval Represents Key Advance for Patients With Blood Cancers Requiring Transplant

Birtamimab Under Investigation in Mayo Stage IV AL Amyloidosis

ASCO 2023 Insights: ADCS, Next-Generation TKIs, and More Lead Data Pack Ahead of Annual Meeting

Andreeff Sheds Light on the Evaluation of the E-selectin Antagonist Uproleselan in AML

Voruciclib With or Without Venetoclax Shows Safety, Activity in R/R AML, B-cell Malignancies

FDA Approval Insights: Omidubicel in Blood Cancers Requiring Transplant

Omidubicel Approval Represents Key Advance for Patients With Blood Cancers Requiring Transplant

Birtamimab Under Investigation in Mayo Stage IV AL Amyloidosis

Related Content

Jane Meisel, MD

ASCO 2023 Insights: ADCS, Next-Generation TKIs, and More Lead Data Pack Ahead of Annual Meeting

Michael Andreeff, MD, PhD

Andreeff Sheds Light on the Evaluation of the E-selectin Antagonist Uproleselan in AML

Image Credit: ©freshidea - stock.adobe.com

Voruciclib With or Without Venetoclax Shows Safety, Activity in R/R AML, B-cell Malignancies

Mitchell E. Horwitz, MD

FDA Approval Insights: Omidubicel in Blood Cancers Requiring Transplant

Mitchell E. Horwitz, MD

Omidubicel Approval Represents Key Advance for Patients With Blood Cancers Requiring Transplant

Morie A. Gertz, MD

Birtamimab Under Investigation in Mayo Stage IV AL Amyloidosis

Latest Conference Coverage

ASCO 2023 Insights: ADCS, Next-Generation TKIs, and More Lead Data Pack Ahead of Annual Meeting

Sacituzumab Govitecan Elicits Consistent Safety in Patients With HR+/HER2– Breast Cancer, Regardless of UGT1A1 Status

Atezolizumab Plus Trastuzumab/Vinorelbine Elicits Responses in HER2+ Advanced Breast Cancer

Medicaid Expansion Improves Survival in Pancreatic, Gastric Cancers, Potentially Reducing Disparities

View More Latest Conference Coverage

Editorial Board

CancerNetwork.com

OncNursingNews.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.